Full Press Release Details
argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis.
ARGX
argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
Key Takeaway: argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis